Phenome Register — human experiences and functional states across cognitive, emotional, social, lifestyle, health, physical performance, and mental wellbeing domains

Phenome Registry

The BRAIN Phenome Knowledge Database intentionally applies a narrower operational definition of "phenome" than is used in the wider phenomics literature. Although phenomes may include physiological and metabolic characteristics, the purpose of this registry is to catalogue human functional outcomes that are meaningful within cognitive, behavioural and mental health contexts. Biological capacities such as ATP production, fuel switching, mitochondrial substrate flexibility, or adaptive/allostatic metabolic resilience remain important, but are represented as emergent properties of coordinated Biological Regulatory Systems performance rather than as standalone phenomes.

The registry is scoped to neuropsychiatric and neurocognitive health. ADHD (TA001) is the primary worked example in Version 1; the architecture supports anxiety, depression, autism spectrum, cognitive ageing, long COVID, and healthy cognitive optimisation without duplicating phenome labels per condition.

Mechanism-to-phenome links are translational relationships. They do not imply that a single mechanism causes or treats a complex condition.

Phenome development

Candidate phenomes were developed within the BRAIN Framework as functional outcome domains linking biological regulatory systems to clinically relevant cognitive, behavioural, emotional, social, and physiological capacities. During development, the registry was compared with established research frameworks, including the NIH Research Domain Criteria (RDoC), to identify omissions, reduce overlap between phenomes, and improve construct separation. These external frameworks were used to validate and refine the taxonomy rather than define its structure. The BRAIN Phenome Registry therefore represents an independent translational classification informed by, but not derived from, existing neuropsychiatric research frameworks.

NIH Research Domain Criteria (benchmark) — Used to identify omissions, reduce phenome overlap, and improve construct separation — not the defining taxonomy.
WHO International Classification of Functioning, Disability and Health (benchmark) — Optional cross-reference for activity and participation domains where clinically relevant.

Therapeutic areas

ID	Therapeutic area	Description
TA001	ADHD — primary V1 example	Attention-deficit/hyperactivity disorder and related executive-function, impulsivity, and hyperactivity phenotypes.
TA002	Anxiety Disorders	Generalised anxiety, social anxiety, panic, and related hyperarousal and worry phenotypes.
TA003	Depressive Disorders	Major depression, dysthymia, and related motivational, affective, and cognitive slowing phenotypes.
TA004	Autism Spectrum	Autism spectrum conditions and related sensory, social-cognitive, and regulatory phenotypes.
TA005	Cognitive Ageing	Age-related cognitive decline, mild cognitive impairment, and dementia-risk cognitive phenotypes.
TA006	Long COVID	Post-acute infection syndromes with cognitive, fatigue, and autonomic phenotypes.
TA007	Healthy Cognitive Optimisation	Non-clinical cognitive performance, resilience, and brain-health optimisation contexts.

Registry overview

These are three independent scores. They are not combined or averaged. A phenome can have Medium registry evidence while individual mechanism rows show different relationship strength and evidence scores.

1. Phenome Evidence Confidence (Phenome Registry only)

Question: How convincing is the foundational evidence that this phenome is a valid, well-defined functional construct — and that diet-relevant biology can plausibly connect to it?

Not a roll-up of Biology → Phenome Relationship Strength or Evidence Confidence from Primary Mechanism page rows. Those are scored per mechanism; this score is assigned once per phenome at registry level.

Derived from foundational landmark evidence organised in up to three layers: construct validation, biology→phenome linkage, and nutrition→biology modulation. Each layer may include one or many landmark papers depending on registry review.

2. Biology → Phenome Relationship Strength (Primary Mechanism phenome rows)

Question: If this PM/FM biology were substantially impaired in isolation, how directly would that phenome be expected to suffer — within BRAIN architecture?

How it is derived: Reviewers read the PM/FM definition and biological function first — initially ignoring attached references and whether dietary intervention studies exist. References are reviewed only when scoring Evidence Confidence (below).

Score levels (the value shown on each row as Biology → Phenome Relationship Strength):

High — primary biological determinant (e.g. noradrenergic signalling → attention; GABA synthesis → calming tone)
Medium — major contributory determinant, not the sole driver
Low–Medium — established but indirect, modulatory, or one integrative step removed
Low — distal, conditional, or weak biological coupling

“Not dietary treatment efficacy” means this score does not ask whether a diet or supplement treats the phenome. It asks whether the biology itself is architecturally relevant. Limited dietary RCT evidence belongs in Evidence Confidence, not here.

3. Evidence Confidence (Primary Mechanism phenome rows)

Question: How convincing is the adjudicated evidence on that specific row that this biology actually relates to this phenome?

How it is derived: Assigned after Biology → Phenome Relationship Strength, by reviewing the relationship evidence on that PM/FM row. Judges whether the evidence supports the relationship — not just mechanism or phenome in isolation.

High — strong convergent human evidence directly linking mechanism biology to phenome variation
Medium — multiple human lines supporting the relationship; may include one bridge study with an inferential step
Low–Medium — convergent translational stack without direct mechanism↔phenome measurement on the row
Low — mechanistic or preclinical only; mechanism and phenome supported separately but not bridged

Often equal to or lower than Biology → Phenome Relationship Strength. Can occasionally be higher when outcome evidence is stronger than the mechanism's contributory role.

Filter by therapeutic areaShowing 15 of 15 phenomes

ID	Phenome	Description	Therapeutic areas	Phenome Evidence Confidence	Connected Mechanisms
PH001	Focus / Attention Stability	Capacity to sustain, shift, and regulate attention across changing cognitive demands.	TA001 ★TA002TA004TA005TA006TA007	Low–Medium	21 mechanisms BRS-X(Hormones-PM1) — Oestrogen Signalling Stabilityindirect · Relationship Strength: Low–Medium · Evidence: Low–Medium BRS1-FM1-PM1 — Amino-Acid Availability & Prioritisationmodulates · Relationship Strength: Low–Medium · Evidence: Low–Medium BRS1-FM1-PM2 — LAT1 Competitive Transport Modulationmodulates · Relationship Strength: Low–Medium · Evidence: Low–Medium BRS1-FM1-PM3 — Dopaminergic Signalling Regulationmodulates · Relationship Strength: High · Evidence: Medium BRS1-FM1-PM4 — Noradrenergic Signallingmodulates · Relationship Strength: High · Evidence: Low–Medium BRS1-FM2-PM6 — Acetylcholine Synthesis Supportmodulates · Relationship Strength: Low–Medium · Evidence: Low–Medium BRS1-FM3-PM7 — Neuronal Membrane DHA Incorporationmodulates · Relationship Strength: Low–Medium · Evidence: Low–Medium BRS1-FM4-PM10 — Glutamate Clearance & Recyclingmodulates · Relationship Strength: Low–Medium · Evidence: Low–Medium BRS2-FM1-PM1 — Folate/B12-Dependent Homocysteine Remethylationmodulates · Relationship Strength: Low–Medium · Evidence: Low–Medium BRS2-FM1-PM2 — Betaine/BHMT Remethylationmodulates · Relationship Strength: Low–Medium · Evidence: Low–Medium BRS2-FM1-PM4 — Methionine Cycle Fluxmodulates · Relationship Strength: Low–Medium · Evidence: Low–Medium BRS2-FM3-PM7 — Phosphatidylcholine Formationmodulates · Relationship Strength: Low–Medium · Evidence: Low–Medium BRS3-FM1-PM1 — NF-kB Signalling Regulationmodulates · Relationship Strength: Low–Medium · Evidence: Low–Medium BRS3-FM1-PM2 — Gut-Derived Inflammatory Signallingmodulates · Relationship Strength: Low–Medium · Evidence: Low–Medium BRS3-FM2-PM3 — Nrf2-Mediated Cellular Defence Regulationmodulates · Relationship Strength: Low–Medium · Evidence: Low–Medium BRS3-FM2-PM4 — ROS Generation vs Clearance Balancemodulates · Relationship Strength: Low–Medium · Evidence: Low–Medium BRS3-FM2-PM5 — Lipid Peroxidation Controlmodulates · Relationship Strength: Low–Medium · Evidence: Low–Medium BRS3-FM3-PM7 — Cytokine Network Modulationmodulates · Relationship Strength: Low–Medium · Evidence: Low–Medium BRS3-FM3-PM8 — Eicosanoid / SPM Balancemodulates · Relationship Strength: Low · Evidence: Low BRS4-FM1-PM1 — Electron Transport Chain Functionmodulates · Relationship Strength: Low–Medium · Evidence: Low–Medium BRS4-FM3-PM6 — Carnitine-Mediated Fat Transportmodulates · Relationship Strength: Medium · Evidence: Medium
PH002	Motivation / Drive	Capacity to initiate effort, pursue goals, and maintain goal-directed behaviour.	TA001 ★TA003TA004TA007	Low–Medium	8 mechanisms BRS-X(ECS-PM1) — NAPE → NAE Biosynthesis Capacitysupports · Relationship Strength: Low–Medium · Evidence: Low–Medium BRS-X(ECS-PM4) — Endocannabinoid–Dopamine Neuromodulationsupports · Relationship Strength: Low–Medium · Evidence: Low–Medium BRS-X(Hormones-PM5) — Testosterone Signalling Stabilitysupports · Relationship Strength: Medium · Evidence: Medium BRS-X(Hormones-PM6) — Androgen-Microbiome Regulationindirect · Relationship Strength: Low · Evidence: Low BRS1-FM1-PM1 — Amino-Acid Availability & Prioritisationmodulates · Relationship Strength: Low–Medium · Evidence: Low–Medium BRS1-FM1-PM2 — LAT1 Competitive Transport Modulationmodulates · Relationship Strength: Low–Medium · Evidence: Low–Medium BRS1-FM1-PM3 — Dopaminergic Signalling Regulationmodulates · Relationship Strength: High · Evidence: Medium BRS1-FM1-PM4 — Noradrenergic Signallingmodulates · Relationship Strength: Medium · Evidence: Low–Medium
PH003	Emotional Regulation	Capacity to modulate emotional responses and maintain affective stability.	TA001 ★TA002TA003TA004TA006	Low–Medium	22 mechanisms BRS-X(ECS-PM1) — NAPE → NAE Biosynthesis Capacitymodulates · Relationship Strength: Low · Evidence: Low BRS-X(ECS-PM2) — Omega-3-Derived Endocannabinoidome Signallingmodulates · Relationship Strength: Low · Evidence: Low BRS-X(ECS-PM3) — FAAH-Mediated Endocannabinoid Preservationmodulates · Relationship Strength: Low · Evidence: Low BRS-X(ECS-PM5) — Endocannabinoid Stress-Buffering Capacitymodulates · Relationship Strength: Low–Medium · Evidence: Low–Medium BRS-X(Hormones-PM1) — Oestrogen Signalling Stabilitymodulates · Relationship Strength: Low–Medium · Evidence: Low–Medium BRS-X(Hormones-PM2) — Estrobolome Regulationmodulates · Relationship Strength: Low–Medium · Evidence: Low–Medium BRS-X(Hormones-PM3) — Progesterone-Supportive Microbial Metabolismmodulates · Relationship Strength: Low · Evidence: Low BRS-X(Hormones-PM4) — Metabolic-Reproductive Hormone Integrationindirect · Relationship Strength: Low · Evidence: Low BRS-X(Hormones-PM5) — Testosterone Signalling Stabilitymodulates · Relationship Strength: Low · Evidence: Low BRS-X(Hormones-PM6) — Androgen-Microbiome Regulationindirect · Relationship Strength: Low · Evidence: Low BRS1-FM1-PM1 — Amino-Acid Availability & Prioritisationmodulates · Relationship Strength: Low · Evidence: Low BRS1-FM1-PM2 — LAT1 Competitive Transport Modulationmodulates · Relationship Strength: Low · Evidence: Low BRS1-FM1-PM5 — Serotonergic Signalling Regulationsupports · Relationship Strength: High · Evidence: Low–Medium BRS1-FM3-PM7 — Neuronal Membrane DHA Incorporationmodulates · Relationship Strength: Medium · Evidence: Medium BRS1-FM4-PM9 — GABA Synthesis Capacitymodulates · Relationship Strength: Medium · Evidence: Medium BRS2-FM1-PM3 — SAMe Synthesisindirect · Relationship Strength: Low–Medium · Evidence: Low BRS3-FM1-PM1 — NF-kB Signalling Regulationmodulates · Relationship Strength: Low · Evidence: Low–Medium BRS3-FM1-PM2 — Gut-Derived Inflammatory Signallingmodulates · Relationship Strength: Low · Evidence: Low BRS3-FM2-PM4 — ROS Generation vs Clearance Balancemodulates · Relationship Strength: Low · Evidence: Low–Medium BRS3-FM2-PM5 — Lipid Peroxidation Controlmodulates · Relationship Strength: Low · Evidence: Low BRS3-FM2-PM6 — Antioxidant Network Recyclingmodulates · Relationship Strength: Low · Evidence: Low–Medium BRS3-FM3-PM8 — Eicosanoid / SPM Balancemodulates · Relationship Strength: Low–Medium · Evidence: Low–Medium
PH004	Cognitive Energy Stability	Capacity to maintain mental energy and avoid cognitive energy crashes across the day.	TA001 ★TA003TA005TA006TA007	Low–Medium	10 mechanisms BRS-X(Hormones-PM4) — Metabolic-Reproductive Hormone Integrationmodulates · Relationship Strength: Low–Medium · Evidence: Low–Medium BRS-X(Hormones-PM5) — Testosterone Signalling Stabilitymodulates · Relationship Strength: Low–Medium · Evidence: Medium BRS-X(Hormones-PM6) — Androgen-Microbiome Regulationindirect · Relationship Strength: Low · Evidence: Low BRS1-FM1-PM3 — Dopaminergic Signalling Regulationindirect · Relationship Strength: Low–Medium · Evidence: Low–Medium BRS4-FM1-PM1 — Electron Transport Chain Functionmodulates · Relationship Strength: Low–Medium · Evidence: Low–Medium BRS4-FM1-PM2 — NAD⁺ Metabolismmodulates · Relationship Strength: Low–Medium · Evidence: Low–Medium BRS4-FM1-PM3 — Creatine–Phosphocreatine Energy Bufferingmodulates · Relationship Strength: Low–Medium · Evidence: Low–Medium BRS4-FM3-PM6 — Carnitine-Mediated Fat Transportmodulates · Relationship Strength: Low–Medium · Evidence: Low–Medium BRS4-FM3-PM7 — Ketone Utilisation Capacityindirect · Relationship Strength: Low · Evidence: Low BRS4-FM3-PM8 — Metabolic Fuel Switchingindirect · Relationship Strength: Low–Medium · Evidence: Low
PH005	Recovery Capacity	Capacity to restore function after cognitive, emotional, metabolic, or physical load.	TA001 ★TA005TA006TA007	Low–Medium	9 mechanisms BRS-X(ECS-PM5) — Endocannabinoid Stress-Buffering Capacitymodulates · Relationship Strength: Low · Evidence: Low BRS1-FM4-PM11 — Excitotoxicity Modulationmodulates · Relationship Strength: Low · Evidence: Low BRS2-FM2-PM5 — Transsulfuration Pathwayindirect · Relationship Strength: Low · Evidence: Low BRS2-FM2-PM6 — Glutathione Synthesismodulates · Relationship Strength: Low–Medium · Evidence: Low–Medium BRS4-FM1-PM2 — NAD⁺ Metabolismindirect · Relationship Strength: Low · Evidence: Low BRS4-FM1-PM3 — Creatine–Phosphocreatine Energy Bufferingindirect · Relationship Strength: Low · Evidence: Low BRS4-FM2-PM4 — ROS Production and Controlmodulates · Relationship Strength: Low–Medium · Evidence: Low–Medium BRS4-FM2-PM5 — Mitochondrial Protection (Redox Integrity)modulates · Relationship Strength: Low–Medium · Evidence: Low–Medium BRS4-FM4-PM9 — Mitochondrial Biogenesismodulates · Relationship Strength: Low–Medium · Evidence: Low–Medium
PH006	Stress Resilience	Capacity to buffer, adapt to, and recover from stress exposure.	TA001 ★TA002TA003TA006	Low–Medium	9 mechanisms BRS-X(ECS-PM1) — NAPE → NAE Biosynthesis Capacitymodulates · Relationship Strength: Low–Medium · Evidence: Low–Medium BRS-X(ECS-PM2) — Omega-3-Derived Endocannabinoidome Signallingmodulates · Relationship Strength: Low–Medium · Evidence: Low–Medium BRS-X(ECS-PM3) — FAAH-Mediated Endocannabinoid Preservationmodulates · Relationship Strength: Low–Medium · Evidence: Low–Medium BRS-X(ECS-PM5) — Endocannabinoid Stress-Buffering Capacitysupports · Relationship Strength: Low–Medium · Evidence: Low–Medium BRS1-FM1-PM5 — Serotonergic Signalling Regulationsupports · Relationship Strength: Low–Medium · Evidence: Low–Medium BRS2-FM2-PM6 — Glutathione Synthesismodulates · Relationship Strength: Low–Medium · Evidence: Low–Medium BRS3-FM2-PM3 — Nrf2-Mediated Cellular Defence Regulationmodulates · Relationship Strength: Low · Evidence: Low BRS3-FM2-PM6 — Antioxidant Network Recyclingmodulates · Relationship Strength: Low–Medium · Evidence: Medium BRS4-FM2-PM5 — Mitochondrial Protection (Redox Integrity)modulates · Relationship Strength: Low–Medium · Evidence: Low–Medium
PH008	Sleep / Calming Tone	Capacity to downshift arousal and support sleep-compatible physiological regulation.	TA001 ★TA002TA004TA006	Low–Medium	3 mechanisms BRS-X(Hormones-PM3) — Progesterone-Supportive Microbial Metabolismindirect · Relationship Strength: Low · Evidence: Low BRS1-FM1-PM5 — Serotonergic Signalling Regulationsupports · Relationship Strength: Medium · Evidence: Low BRS1-FM4-PM9 — GABA Synthesis Capacitymodulates · Relationship Strength: High · Evidence: Low
PH009	Reward Regulation	Capacity to regulate reward sensitivity, reinforcement learning, and reward-seeking behaviour.	TA001 ★TA002TA003TA007	Low	2 mechanisms BRS-X(ECS-PM4) — Endocannabinoid–Dopamine Neuromodulationmodulates · Relationship Strength: Low–Medium · Evidence: Low–Medium BRS1-FM1-PM5 — Serotonergic Signalling Regulationmodulates · Relationship Strength: Low · Evidence: Low
PH010	Behavioural Activation	Capacity to translate motivation into action, task initiation, and sustained behavioural engagement.	TA001 ★TA003TA007	Low	1 mechanism BRS-X(ECS-PM4) — Endocannabinoid–Dopamine Neuromodulationmodulates · Relationship Strength: Low · Evidence: Low
PH011	Cognitive Clarity	Capacity to maintain clear, organised mental processing without excessive fog or confusion.	TA001 ★TA002TA003TA004TA005TA006TA007	Low–Medium	19 mechanisms BRS-X(ECS-PM2) — Omega-3-Derived Endocannabinoidome Signallingmodulates · Relationship Strength: Low · Evidence: Low BRS-X(Hormones-PM1) — Oestrogen Signalling Stabilitymodulates · Relationship Strength: Low–Medium · Evidence: Low–Medium BRS-X(Hormones-PM2) — Estrobolome Regulationindirect · Relationship Strength: Low–Medium · Evidence: Low–Medium BRS1-FM2-PM6 — Acetylcholine Synthesis Supportmodulates · Relationship Strength: Medium · Evidence: Low BRS1-FM3-PM7 — Neuronal Membrane DHA Incorporationmodulates · Relationship Strength: Low–Medium · Evidence: Low–Medium BRS1-FM4-PM10 — Glutamate Clearance & Recyclingmodulates · Relationship Strength: Low · Evidence: Low BRS2-FM1-PM1 — Folate/B12-Dependent Homocysteine Remethylationmodulates · Relationship Strength: Low–Medium · Evidence: Low BRS2-FM1-PM2 — Betaine/BHMT Remethylationindirect · Relationship Strength: Low · Evidence: Low BRS2-FM1-PM3 — SAMe Synthesismodulates · Relationship Strength: Medium · Evidence: Low–Medium BRS2-FM1-PM4 — Methionine Cycle Fluxmodulates · Relationship Strength: Low–Medium · Evidence: Low–Medium BRS2-FM3-PM7 — Phosphatidylcholine Formationmodulates · Relationship Strength: Medium · Evidence: Low–Medium BRS3-FM1-PM1 — NF-kB Signalling Regulationmodulates · Relationship Strength: Low–Medium · Evidence: Medium BRS3-FM1-PM2 — Gut-Derived Inflammatory Signallingmodulates · Relationship Strength: Low–Medium · Evidence: Low–Medium BRS3-FM2-PM3 — Nrf2-Mediated Cellular Defence Regulationmodulates · Relationship Strength: Low–Medium · Evidence: Medium BRS3-FM2-PM4 — ROS Generation vs Clearance Balancemodulates · Relationship Strength: Low–Medium · Evidence: Low–Medium BRS3-FM2-PM5 — Lipid Peroxidation Controlmodulates · Relationship Strength: Low–Medium · Evidence: Low–Medium BRS3-FM2-PM6 — Antioxidant Network Recyclingmodulates · Relationship Strength: Low–Medium · Evidence: Low–Medium BRS3-FM3-PM7 — Cytokine Network Modulationmodulates · Relationship Strength: Low · Evidence: Low–Medium BRS3-FM3-PM8 — Eicosanoid / SPM Balancemodulates · Relationship Strength: Low–Medium · Evidence: Low–Medium
PH014	Hormonal Volatility	Stability of hormone-linked signalling patterns that influence mood, cognition, and physiological regulation.	TA001 ★TA002TA003TA004	Low–Medium	2 mechanisms BRS-X(Hormones-PM2) — Estrobolome Regulationmodulates · Relationship Strength: Low–Medium · Evidence: Low–Medium BRS-X(Hormones-PM4) — Metabolic-Reproductive Hormone Integrationmodulates · Relationship Strength: Low–Medium · Evidence: Low–Medium
PH015	Stress Reactivity	Intensity and pattern of physiological and affective responses to stressors.	TA001 ★TA002TA004TA006	Low–Medium	4 mechanisms BRS-X(Hormones-PM3) — Progesterone-Supportive Microbial Metabolismindirect · Relationship Strength: Low · Evidence: Low BRS1-FM4-PM11 — Excitotoxicity Modulationmodulates · Relationship Strength: Low · Evidence: Low BRS2-FM2-PM5 — Transsulfuration Pathwaymodulates · Relationship Strength: Low–Medium · Evidence: Low–Medium BRS4-FM2-PM4 — ROS Production and Controlmodulates · Relationship Strength: Low–Medium · Evidence: Low–Medium
PH016	Apprehensive Worry / Perseverative Thought	Capacity to limit sustained apprehensive worry, rumination, and difficulty disengaging from threat-anticipatory or negative perseverative thought.	TA001 ★TA002TA003TA006	Medium	6 mechanisms BRS1-FM1-PM5 — Serotonergic Signalling Regulationsupports · Relationship Strength: Low–Medium · Evidence: Low–Medium BRS1-FM4-PM9 — GABA Synthesis Capacitymodulates · Relationship Strength: Low–Medium · Evidence: Low–Medium BRS3-FM1-PM1 — NF-kB Signalling Regulationmodulates · Relationship Strength: Low–Medium · Evidence: Low–Medium BRS3-FM1-PM2 — Gut-Derived Inflammatory Signallingmodulates · Relationship Strength: Low–Medium · Evidence: Low–Medium BRS3-FM3-PM7 — Cytokine Network Modulationmodulates · Relationship Strength: Medium · Evidence: Medium BRS3-FM3-PM8 — Eicosanoid / SPM Balancemodulates · Relationship Strength: Medium · Evidence: Medium
PH017	Pleasure & Interest Capacity	Capacity to experience interest, anticipatory pleasure, and consummatory engagement with rewarding or meaningful activities — the functional domain overlapping anhedonia in depressive and related conditions.	TA001 ★TA002TA003TA007	Low–Medium	5 mechanisms BRS1-FM1-PM4 — Noradrenergic Signallingmodulates · Relationship Strength: Low–Medium · Evidence: Low BRS1-FM1-PM5 — Serotonergic Signalling Regulationmodulates · Relationship Strength: Low–Medium · Evidence: Low–Medium BRS3-FM1-PM1 — NF-kB Signalling Regulationmodulates · Relationship Strength: Low · Evidence: Low–Medium BRS3-FM3-PM7 — Cytokine Network Modulationmodulates · Relationship Strength: Low · Evidence: Low–Medium BRS3-FM3-PM8 — Eicosanoid / SPM Balancemodulates · Relationship Strength: Low · Evidence: Low–Medium
PH018	Social Engagement Capacity	Capacity for affiliative approach, social participation, and maintained engagement in interpersonal contexts without excessive withdrawal or avoidance.	TA002TA003TA004TA007	Low–Medium	3 mechanisms BRS1-FM1-PM5 — Serotonergic Signalling Regulationmodulates · Relationship Strength: Low · Evidence: Low BRS1-FM4-PM9 — GABA Synthesis Capacityindirect · Relationship Strength: Low · Evidence: Low BRS3-FM1-PM2 — Gut-Derived Inflammatory Signallingindirect · Relationship Strength: Low · Evidence: Low–Medium

Phenome details

Each registered phenome has a dedicated detail page with provenance, cross-references, foundational evidence, and connected mechanisms. Browse from the Phenome details section in the sidebar, or open a phenome from the table above.

Registry review flags

The following phenome pairs are flagged for manual review (not merged automatically).

RF002 (related_distinct): Stress Resilience (adaptive capacity) vs Stress Reactivity (response intensity) — related but not identical; do not merge automatically. — Stress Resilience / Stress Reactivity
RF003 (related_distinct): Motivation/Drive vs Behavioural Activation — related; remain separate unless manually merged. — Motivation / Drive / Behavioural Activation
RF004 (related_distinct): Emotional Regulation (affective modulation) vs Apprehensive Worry (sustained apprehensive/ruminative cognition) — RDoC Negative Valence / cognitive control overlap; remain separate. — Emotional Regulation / Apprehensive Worry / Perseverative Thought
RF005 (related_distinct): Reward Regulation (sensitivity, learning, seeking) vs Pleasure & Interest Capacity (experienced interest/pleasure and consummatory engagement) — RDoC Positive Valence / anhedonia domain; remain separate. — Reward Regulation / Pleasure & Interest Capacity
RF006 (related_distinct): Emotional Regulation vs Social Engagement Capacity (affiliation, approach, participation) — RDoC Social Processes; remain separate. — Emotional Regulation / Social Engagement Capacity